Welcome to our dedicated page for Eledon Pharmaceuticals SEC filings (Ticker: ELDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eledon Pharmaceuticals, Inc. (ELDN) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Eledon is a clinical stage biotechnology company focused on immune-modulating therapies built around the CD40 Ligand (CD40L) pathway, with its common stock listed on the Nasdaq Capital Market under the symbol ELDN, as noted in its Form 8-K filings.
Through this page, readers can review key documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe Eledon’s clinical programs for its lead investigational product tegoprubart, risk factors, and financial position. Current reports on Form 8-K provide more targeted updates, including material events related to clinical data disclosures, financing transactions and other significant corporate developments.
For example, an 8-K dated November 12, 2025 outlines an underwriting agreement for an underwritten public offering of common stock and pre-funded warrants, including the intended use of net proceeds to support continued clinical development and pipeline advancement. Other 8-K filings describe preliminary cash, cash equivalents and short-term investment balances, as well as press releases announcing Phase 2 BESTOW trial results and updated data from a Phase 1b kidney transplant study.
On Stock Titan, these filings are supplemented by AI-powered summaries that explain the main points of lengthy documents, helping users quickly understand topics such as capital raises, clinical trial disclosures and selected financial information. Real-time updates from EDGAR allow timely viewing of new ELDN filings, while access to forms like 10-K, 10-Q and 8-K supports deeper analysis of Eledon’s clinical-stage operations, financing activities and risk disclosures.
Eledon Pharmaceuticals Inc amendment to a Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned, representing 0% of the common stock. The filing explains an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries to report separately.
Eledon Pharmaceuticals reported a 2025 net loss of $45.6 million, wider than $36.2 million in 2024, as it increased investment in its lead antibody tegoprubart, mainly for kidney transplant studies. Research and development spending rose to $66.3 million, while general and administrative costs declined to $17.0 million.
The company ended 2025 with cash, cash equivalents and short-term investments of $133.3 million and working capital of $117.3 million, and expects this to fund operations for at least 12 months. Management states additional capital will be needed to advance programs beyond that period and to continue clinical development of tegoprubart for ALS.
Eledon Pharmaceuticals reported fourth quarter and full year 2025 results and highlighted progress for its lead antibody tegoprubart in multiple transplant settings. The FDA granted Orphan Drug designation for preventing allograft rejection in liver transplantation, adding to prior orphan designations in islet cell transplantation and ALS.
In a Phase 1b kidney transplant extension study, eight patients followed for 24 months had no biopsy-proven acute rejection, graft loss, death, new-onset diabetes, or de novo donor-specific antibodies, while mean eGFR rose from 67.0 to 74.2 mL/min/1.73 m². In a UChicago islet transplant trial for type 1 diabetes, all 10 evaluable patients achieved insulin independence with most recent HbA1c below 6.0% and a mean of about 5.35%, with no rejection or typical tacrolimus-related toxicities.
For 2025, research and development expenses were $66.3 million versus $52.0 million in 2024, and general and administrative expenses were $17.0 million versus $18.6 million. Net loss was $45.6 million, or $0.52 per common share, compared to a $36.2 million loss, or $0.66 per share, in 2024. Results included non-cash gains from changes in warrant liabilities of $33.4 million in 2025 and $30.9 million in 2024.
Eledon Pharmaceuticals, Inc. received an amended Schedule 13G from RA Capital Management and related reporting persons regarding its common stock. As of December 31, 2025, RA Capital Management, Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. each report beneficial ownership of 0 shares and 0.0% of the common stock, with no sole or shared voting or dispositive power. The filers also certify that the securities referenced were not acquired and are not held for the purpose of changing or influencing control of Eledon Pharmaceuticals.
Coastlands-affiliated funds and Matthew D. Perry report minority ownership in Eledon Pharmaceuticals, Inc. on an amended Schedule 13G. Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Perry collectively report beneficial ownership of 3,937,826 shares of Eledon common stock, representing 4.99% of the class.
This position includes 450,000 shares held directly by Coastlands Capital LP and 3,487,826 shares issuable upon exercise of pre-funded warrants, all subject to a 4.99% beneficial ownership limitation. Perry’s reported beneficial ownership of 3,908,467 shares includes additional stock held through a trust. The filers state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Eledon.
BlackRock, Inc. has filed an amended ownership report showing that it beneficially owns 3,625,824 shares of Eledon Pharmaceuticals, Inc. common stock, representing 4.6% of the outstanding class as of the event date. BlackRock reports sole voting power over 3,584,479 shares and sole dispositive power over 3,625,824 shares, with no shared voting or dispositive power.
The filing states that these securities are held by certain BlackRock business units in the ordinary course of business and are not held for the purpose of changing or influencing control of Eledon Pharmaceuticals. The filing also notes that various underlying clients and investors have rights to dividends or sale proceeds, but no single person has more than five percent of Eledon’s total outstanding common shares.
Eledon Pharmaceuticals director John McBride reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 3,430 restricted stock units were converted into 3,430 shares of Eledon Pharmaceuticals common stock at a price of $0 per share. These RSUs had been granted on January 10, 2025 and vested 100% one year later. Following this transaction, McBride directly holds 3,430 shares of common stock.
Eledon Pharmaceuticals director Jan Hillson reported the vesting and settlement of 3,430 restricted stock units into 3,430 shares of common stock. The transaction occurred on January 10, 2026 through an option exercise coded "M" at a price of $0 per share. The RSUs were originally granted on January 10, 2025 and vested in full one year later, delivering common shares to the director on a one-for-one basis. Following this transaction, Hillson directly holds 3,430 shares of Eledon Pharmaceuticals common stock.
Eledon Pharmaceuticals director Allan Kirk reported acquiring common shares through the vesting of equity awards. On January 10, 2026, 3,430 restricted stock units (RSUs) that had been granted on January 10, 2025 vested in full and were settled into 3,430 shares of Eledon Pharmaceuticals common stock on a one-for-one basis.
The RSU settlement was reported at a price of $0 per share, reflecting that no cash was paid in this conversion. Following the transaction, Allan Kirk beneficially owned 3,430 shares of common stock directly.
Eledon Pharmaceuticals director Keith Katkin reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 8,575 restricted stock units converted into 8,575 shares of Eledon Pharmaceuticals common stock at a price of $0 per share, reflected as a transaction coded "M". These RSUs were originally granted on January 10, 2025 and vested 100% on January 10, 2026. Following the transaction, Katkin beneficially owned 8,575 shares of common stock directly.